Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 5/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232476 | 0.79 | ALDH1A1 (0.46) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL17221463 | 0.77 | ALDH1A1 (0.45) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL29911448 | 0.77 | ALDH1A1 (0.49) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL23088012 | 0.77 | ALDH1A1 (0.49) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL23088260 | 0.75 | KDM4E (0.50) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL17229331 | 0.75 | AR (0.46) | IMPDH2IMPDH1HTR2AALDH1A1KDM4E | |
| SCHEMBL27033473 | 0.74 | ALDH1A1 (0.43) | IMPDH2IMPDH1KLKB1F11ALDH1A1 | |
| SCHEMBL9723166 | 0.72 | ALDH1A1 (0.53) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| Zinc Ion SCHEMBL30711601 | 0.71 | ALDH1A1 (0.40) | IMPDH2IMPDH1KLKB1F11ALDH1A1 | |
| SCHEMBL29174266 | 0.71 | ALDH1A1 (0.40) | IMPDH2IMPDH1KLKB1F11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-10611758-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2019-10-31 | — | — | US | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4386/4885IMPDH1 3992/4885KLKB1 1/4885 |
| US-10611758-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4449/4885IMPDH1 4083/4885KLKB1 1/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4386/4885IMPDH1 3992/4885KLKB1 1/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4515/4885IMPDH1 4170/4885KLKB1 1/4885 |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4449/4885IMPDH1 4083/4885KLKB1 1/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IMPDH2 4515/4885IMPDH1 4170/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.